Navigation Links
Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea
Date:8/2/2011

ST. PAUL, Minn., Aug. 2, 2011 /PRNewswire/ -- Apnex Medical, Inc., received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a clinical study to evaluate the safety and effectiveness of its Hypoglossal Nerve Stimulation (HGNS®) System to treat obstructive sleep apnea (OSA). Data from this clinical study are intended to support the Pre-Market Approval (PMA) application for the HGNS System to the FDA.

"Many patients who suffer from OSA are unable to tolerate existing therapies such as continuous positive airway pressure (CPAP). The HGNS System provides a fundamentally new approach to the treatment of OSA. This study will help us further understand the potential role this device will have in treating the millions of people who suffer from OSA," said the study's co-principal investigator, Dr. Atul Malhotra, Clinical Chief, Division of Sleep Medicine, Brigham and Women's Hospital.

Sponsored by Apnex Medical, the Apnex Clinical Study is a prospective, randomized, multi-center clinical trial. It is being conducted in leading medical centers in the United States, Europe and Australia. The trial is designed to demonstrate the safety and effectiveness of the HGNS therapy in treating patients with moderate to severe OSA. To be enrolled in the study patients must not have received lasting benefit from CPAP or other OSA treatments.

"We have seen very encouraging results from the HGNS feasibility studies. Results recently presented at the international SLEEP meeting showed that most patients treated with the HGNS System experienced significant improvements in their sleep apnea, sleepiness, and quality of life. This study will help us determine if these results can be demonstrated in a second larger patient population," said the study's co-principal investigator, Dr. Eric Kezirian, Department of Otolaryngology – Head and Neck Surgery, University of California, San Francisco.

About Apnex Medical, Inc. and HGNS System

Apnex Medical was founded in 2006 with a mission to pioneer medical innovations to improve the health of people with sleep disordered breathing. The company has developed a proprietary medical device for the treatment of OSA.

The Apnex HGNS System is an implantable therapy that is intended to work by activating the muscles in the upper airway to ensure that the airway remains open during sleep. The system detects the patient's breathing and delivers mild stimulation to the hypoglossal nerve, the nerve that controls the muscles of the tongue, to keep the airway open. The stimulation is timed to a patient's own breathing pattern. The HGNS System is designed to work only when the patient is asleep through a handheld controller.

About OSA

According to the World Health Organization approximately 100 million people worldwide have OSA. It occurs because of blockage of breathing during sleep. This can deprive OSA sufferers of deep restful sleep and lead to sleepiness and fatigue. OSA sufferers are also at an increased risk for a variety of health conditions, including high blood pressure, coronary artery disease, diabetes and stroke. Untreated OSA is also associated with an increased risk of death. Current OSA treatments are not always successful or well tolerated. The Apnex device is designed to provide an alternative treatment for OSA that addresses these problems.

More information on the Apnex Clinical Study can be found at www.SleepApneaTrial.com. To learn if you might qualify for the study go to this website or call 1-888-975-3370.

To request additional information, please contact:

Apnex Medical, Inc.
2890 Centre Pointe Drive
St. Paul, MN 55113 USA
+1.651.757.4300
www.apnexmedical.com

CAUTION: The Apnex HGNS System is an investigational device and is limited by Federal Law to investigational use.

FOR CLINICAL TRIAL USE ONLY.

Apnex Medical, Apnex and HGNS are registered trademarks of Apnex Medical, Inc.

© Apnex Medical, Inc. 2011 All rights reserved.


'/>"/>
SOURCE Apnex Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Apnex Medical, Inc. Raises Additional $14 Million
2. Apnex Medical, Inc. Names Chas McKhann President, Chief Executive Officer
3. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
4. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
7. New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%
8. Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor
9. Cardiva Medical, Inc. Announces the Departure of its President and his Appointment as CEO of Innovative Energy, Inc.
10. Tenaxis Medical, Inc. Announces Completion of the Enrollment Phase of Their Pivotal Study
11. China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health ... technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing ... form that can be easily incorporated into liquid products, while reducing costs to end ...
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of ... announced today its plans to open a flagship location in Covington, LA at 401 ... Rooms To Go store next to Office Depot in the Holiday Square shopping center. ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):